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Conditions involving severe immune dysregulation are strong risk factors for non-Hodgkin lymphoma (NHL). 1 However, it is unclear whether subclinical immunologic perturbations influence NHL risk. We and other investigators have recently reported NHL associations with elevated prediagnostic serum concentrations of the immune markers soluble CD23 (sCD23), sCD27, sCD30, B-cellattracting chemokine-1 (BCA1), soluble tumor necrosis factor receptor-2 (sTNFR2) and soluble vascular endothelial growth factor receptor-2 (sVEGFR2). [2] [3] [4] [5] [6] [7] Although these findings support a role for immunologic effects in lymphomagenesis, the relatively short duration of follow-up after phlebotomy in these studies (10-13 years) limits the ability to rule out reverse causation as an explanation, given the potential for developing lymphomas to express these markers or indirectly affect their expression. Investigations within cohorts with longer follow-up time are needed to clarify the temporal nature of these associations. To that end, we conducted a nested case-control study investigating the serum levels of these analytes and NHL diagnosed up to 23 years after phlebotomy within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, a cohort with banked fasting serum from 29 133 male Finnish smokers.
The ATBC Study was approved by the institutional review boards of the National Cancer Institute and the National Public Health Institute of Finland; written informed consent was obtained from all the participants. 8 We identified 272 first-primary NHL cases diagnosed 2+ years after phlebotomy through 2009 via the Finnish Cancer Registry. Fifty-three multiple myeloma cases were also selected but excluded from this report. We individually matched controls (N = 325) to cases by baseline age (±2 years), phlebotomy date (±30 days) and the number of previous specimen thaws from among participants alive and cancer-free at case diagnosis. Serum concentrations of the analytes were measured by enzyme-linked immunosorbant assay (sCD23, sCD27, sCD30; Bender Medsystems, Burlingame, CA, USA) and Luminexbased assay (BCA1, sTNFR2, sVEGFR2; EMD Millipore, Billerica, MA, USA). For sCD23, a 1:2 dilution was performed for batches 3 onward to account for low serum volumes for many of the test samples; statistical analyses of this analyte were restricted to these batches. Sera from case-control pairs were assayed consecutively within batches along with blinded quality-control pool replicates (n = 32). Measurements were highly reproducible, with coefficients of variation for log-transformed concentrations o 5%.
Odds ratios (ORs) and 95% confidence intervals (CIs) for analyte concentrations (grouped into three categories using control tertiles as cut points unless otherwise specified; see Table 1 ) were computed using conditional logistic regression analysis adjusting for cigarette pack-years. Trend tests were conducted by modeling intracategory medians as a continuous parameter. Analyses were conducted both overall and stratified across three follow-up periods: 2 to o 8 years (85 cases, median follow-up 5.4 years), 8 to o15 years (101, 11.3) and 15 to o 24 years (86, 19.8). Polytomous regression models were used to compute associations with the two most common histologic subtypes, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; N = 74) and diffuse large B-cell lymphoma (DLBCL; N = 60), adjusting for age, year of phlebotomy, number of prior controlled thaws and cigarette pack-years. Analyses of other NHL subtypes were limited by sparse numbers and are not reported. Analyses stratified by pack-years were conducted using unconditional logistic regression modeling with adjustment for age, year of phlebotomy and number of prior controlled thaws. The statistical analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). All the statistical tests were two-sided.
Cases had higher cigarette pack-years than controls (37.0 vs 33.5 respectively; P = 0.02), but were otherwise comparable for age, body mass index and education level ( Supplementary Table 1 ). sCD27, sCD30, BCA1, sTNFR2 and sVEGFR2 were moderately correlated with one another among controls, with Spearman rank coefficients ranging from 0.21 (BCA1-sVEGFR2) to 0.70 (sTNFR2-sVEGFR2), whereas sCD23 levels were not correlated with other analytes (r = − 0.14 to 0.09).
As summarized in Table 1 , cases had higher serum levels than controls of sCD23 (high category vs low: OR = 2.4, 95% CI = 1.5-3.8, P trend = 0.0005), sCD27 (3.0, 1.8-4.9, P trend o 0.0001), sCD30 (3.3, 1.9-5.5, P trend o0.0001) and sTNFR2 (2.0, 1.2-3.3, P trend = 0.008). When these analytes were modeled simultaneously, associations remained for sCD23 (OR = 1.8, P trend = 0.03), sCD27 (2.1, 0.006) and sCD30 (2.2, 0.02). Associations were apparent for cases diagnosed 15-23 years postphlebotomy for sCD23 (5.1, 1.8-14.6, P trend = 0.002) and sCD30 (3.7, 1.5-9.3, P trend = 0.01), whereas associations with sCD27 and sTNFR2 were strongest for cases diagnosed 2 to o8 years postphlebotomy, and weaker or null in later follow-up periods. The NHL associations with sCD23 and sCD30 did not significantly differ across categories of cigarette pack-years (Supplementary Table 2 ). We observed little evidence of association with BCA1 or sVEGFR2 ( Supplementary Table 3 ).
sCD23 and sCD30 were associated with DLBCL, both overall (sCD23: OR = 2.2, 95% CI = 1.1-4.4, P trend = 0.03; sCD30: 3.9, 1.8-8.2, Accepted article preview online 8 January 2015; advance online publication, 30 January 2015 P trend = 0.0001) and in later follow-up periods (Figure 1 ; results for all analytes in Supplementary Table 4 ). sCD23 was strongly associated with CLL/SLL (5.1, 2.6-10.1, P trend = 0.0001), particularly for cases diagnosed within 2 to o8 years (7.3, 2.1-24.9, P trend = 0.0004) and 8 to o15 years (7.8, 2.5-24.3, P trend = 0.0002) postphlebotomy. sCD30 was not significantly associated with CLL/SLL.
Our findings are consistent with the hypothesis that circulating sCD23 and sCD30, associated with NHL risk as many as 15-23 years after phlebotomy, are biomarkers reflective of immunologic mechanisms contributing to lymphomagenesis. sCD23 and sCD30, the soluble forms of the surface receptors CD23 and CD30, have been proposed to be informative surrogate markers of B-cell activation. 9 Both CD23, a low-affinity IgE receptor, and sCD23 have been shown to induce B-cell stimulatory effects. 10, 11 CD30 is preferentially expressed by activated type-2 T cells, which produce cytokines enhancing B-cell activation. 12, 13 Sustained B-cell activation may contribute to NHL development by increasing the potential for unrepaired lymphomagenic genetic errors. Table 1 . ORs computed through polytomous regression with adjustments for age, year of phlebotomy, number of prior controlled thaws and cigarette pack-years. P-values are from test of trend. We cannot rule out the possibility of occult disease influencing some of our findings, particularly for indolent malignancies such as CLL. Indeed, we observed strong sCD23 associations for CLL/SLL diagnosed closer in time to phlebotomy, which may be at least partly disease induced, as circulating sCD23 in CLL patients has been associated with tumor burden. 14 However, our sCD23 findings for the more aggressive DLBCL are consistent with etiologic effects, given the consistency in associations across follow-up periods and especially the strong risk present even among cases diagnosed 15-23 years after phlebotomy. The weaker NHL associations for sCD27 and sTNFR2 ⩾ 8 years postphlebotomy may reflect diseaseinduced effects, odds ratio attenuation due to a decline in representativeness of one-time analyte measurements as surrogates for usual levels, or both.
The generalizability of these findings is questionable, given that the study population consisted entirely of male Finnish heavy smokers. However, similar NHL and subtype associations with sCD23 and sCD30 have previously been reported, although with fewer years of follow-up, in population-based cohorts that include women (including one all-female cohort) and non-smokers. 3, 4, 6 Our findings raise the possibility that serum sCD23 and sCD30 may hold promise as surrogate end points for cross-sectional studies of suspected B-cell-stimulative risk factors. It is also possible, although speculative, that these markers may have future clinical value in developing risk prediction models. In particular, given the strong association with the CLL/SLL risk observed for elevated sCD23 in serum collected ⩽ 15 years before diagnosis, there is a need to investigate whether the elevated levels of this marker are predictive of future progression to CLL among patients with monoclonal B-cell lymphocytosis, an asymptomatic precursor condition to this malignancy. 15 Studies addressing these questions, particularly using serially collected specimens, are warranted.
